TriangleMelphalan/HDS followed by… (NCT06875128)
Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine) trial for Metastatic Breast Cancer in the Liver (NCT06875128). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with HER2-negative breast cancer whose metastases are mainly in the liver. Prior-treatment requirements include endocrine and CDK4/6 therapy for hormone-receptor-positive disease, and antibody-drug conjugate treatment unless unsuitable or unavailable.
The idea: deliver melphalan into the liver artery under general anesthesia. It damages DNA. Random assignment adds up to two liver treatments to physician-selected eribulin, vinorelbine or capecitabine, or gives the selected drug alone. Researchers assess liver disease control and safety. Liver involvement cannot exceed 50%.
This phase 2 study plans 90 patients. Delcath sponsors five recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.